Motley Fool Asset Management LLC Grows Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Motley Fool Asset Management LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,457 shares of the medical equipment provider’s stock after purchasing an additional 657 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Intuitive Surgical were worth $3,528,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Baystate Wealth Management LLC boosted its stake in shares of Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the period. MCF Advisors LLC lifted its stake in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 40 shares during the period. Atticus Wealth Management LLC lifted its stake in Intuitive Surgical by 85.4% in the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 41 shares during the period. OFI Invest Asset Management purchased a new stake in Intuitive Surgical in the third quarter worth $25,000. Finally, Headinvest LLC purchased a new stake in Intuitive Surgical in the third quarter worth $28,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Down 0.5 %

Shares of Intuitive Surgical stock traded down $1.89 during trading hours on Thursday, reaching $373.12. 1,262,491 shares of the stock traded hands, compared to its average volume of 1,667,548. The company has a 50 day moving average price of $386.26 and a 200 day moving average price of $345.39. The firm has a market capitalization of $132.35 billion, a price-to-earnings ratio of 67.35, a P/E/G ratio of 4.83 and a beta of 1.36. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.00 EPS. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 4.84 earnings per share for the current year.

Insider Activity

In other news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, President David J. Rosa sold 80,710 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total value of $31,418,788.80. Following the transaction, the president now directly owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the transaction, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The disclosure for this sale can be found here. Insiders have sold a total of 255,736 shares of company stock valued at $98,639,667 in the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on ISRG. Piper Sandler raised their price target on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. Mizuho raised their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. BTIG Research raised their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Truist Financial raised their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Finally, StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.